title: High-risk group for locoregional recurrence in patients with stage IB-IIB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.
abstract: OBJECTIVE
  To identify predictive factors for locoregional recurrence in patients with FIGO stage IB-IIB cervical cancer treated with concurrent chemoradiotherapy (CCRT).
  
  
  METHODS
  Data were analyzed for 123 patients with FIGO stage IB-IIB squamous cell carcinoma of the cervix between 1997 and 2007. Eligibility for CCRT included tumor size >4 cm and/or lymph node enlargement over a minimum diameter of 1 cm.
  
  
  RESULTS
  Tumor size (≥5.2 cm) and age (<48 years) were independent predictive factors for locoregional recurrence by multivariate analysis. Based on these two factors, the patients were divided into low-risk (n=91) and high-risk (n=32) groups for locoregional recurrence. The 5-year disease-free survival for the low-risk group was 95.3%, which was significantly better than 65.5% for the high-risk group (p<0.0001). Locoregional recurrence was noted in 10 out of the 32 patients in the high-risk group compared to only 3 out of the 91 patients in the low-risk group.
  
  
  CONCLUSIONS
  To improve locoregional control in the high-risk group, it may be worthwhile to consider CCRT using new radiosensitizing agents, adjuvant hysterectomy or adjuvant chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, University of the Ryukyus, Okinawa 903-0215, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Hirakawa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nagai
authors.forename: Takafumi
authors.initials: T
authors.lastname: Toita
authors.forename: Wataru
authors.initials: W
authors.lastname: Kudaka
authors.forename: Morihiko
authors.initials: M
authors.lastname: Inamine
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Ogawa
authors.forename: Sadayuki
authors.initials: S
authors.lastname: Murayama
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Aoki
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000951:Antigens, Neoplasm / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000628:therapy; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012307:Risk Factors; D015843:Serpins / Q000378:metabolism; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D015843:Serpins; C051072:squamous cell carcinoma-related antigen